John Paulson: Investing Activity (Jan/09)
Print This Story
February 9th, 2009 by MarketFolly.com
Twitter It! | Email This Article
GreenLightAdvisor.com is very pleased to introduce MarketFolly.com as a regular contributing author. MarketFolly.com is devoted to tracking the activities of more than 35 of the most well-known hedge fund managers, their investment activities, as well as providing equity market outlook and analysis. We recently became acquainted with MarketFolly.com’s research, which involves painstakingly combing through SEC filings, among other methods, and felt that this knowledge must be shared with you.
John Paulson’s hedge fund Paulson & Co. has recently filed two 13Gs with the SEC due to activity on December 31st, 2008. Firstly, they have disclosed a 9.24% ownership stake in Rohm & Haas (ROH). The filing shows them owning 18,041,111 shares. ROH was set to be acquired by Dow Chemical (DOW), but the deadline recently passed. Paulson has decided to become more proactive with this position and has sent a letter to Dow Chemical regarding his stance on the merger. Obviously, as a large ROH shareholder, Paulson wants the deal to go through.
Secondly, Paulson & Co has also filed a 13G and has disclosed a 6.6% ownership stake in Boston Scientific (BSX). The filing shows them owning 99,135,000 shares in the company. You can view Paulson’s entire portfolio here. Additionally, Paulson recently filed a 13G on Mirant (MIR) as well.
Paulson & Co has had back-to-back successful years, profiting from the sub-prime mess and overall chaos at financial institutions. Some of their funds finished 2008 up 24% and 37%, as we noted in our year end 2008 Hedge Fund performance numbers summary. Lastly, we also noted that one of Paulson’s co-portfolio managers would be leaving to start his own fund.
Taken from Google Finance,
Rohm & Haas is “a specialty materials company. The Company operates through seven segments: electronic technologies, display technologies, primary materials, paint and coatings materials, packaging and building materials, performance materials group and salt.”
Boston Scientific is “a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties, including interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, oncology, endoscope, urology, gynecology and neuromodulation.”
This article contributed by MarketFolly.com.
MarketFolly.com is a blog providing hedge fund tracking, stock market commentary, and equity analysis. MarketFolly.com compiled a list of 35+ prominent hedge funds that have proven they can outperform over the long-term. We track these hedge fund manager portfolios to share our passion and provide a resource to others. Read more from the author/contributor here.
Related Posts
Tags: Boston Scientific, Bsx, Dow Chemical, Electronic Technologies, ETF, Financial Institutions, Google, Hedge Fund Managers, Hedge Fund Performance, Investment Activities, John Paulson, Market Outlook, Materials Company, Mirant, Ownership Stake, Performance Materials, Performance Numbers, Portfolio Managers, Primary Materials, Proactive, Rohm, Rohm Haas, Sec Filings, Specialty MaterialsPosted in Markets, Outlook |
